Overall, 6 of 101 patients (6%) in the splenectomy group and 3 of

Overall, 6 of 101 patients (6%) in the splenectomy group and 3 of 94 patients (3%) in the non-splenectomy group died within 30 days of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

(not statistically different). Cytopenia contributed to death from sepsis in 4 patients (4%) in the splenectomy group and 1 patient (1%) in the non-splenectomy group (not statistically different). Table 1 Tumor characteristics by splenectomy group The average hospital stay was significantly Inhibitors,research,lifescience,medical different (P=0.001) between the two groups, with the splenectomy group average being 20 days (median 11 days) and the average stay for the non-splenectomy group being 12 days (median 9 days). Dose reduction of mitomycin Inhibitors,research,lifescience,medical C was required in 2 patients in the non-splenectomy group and 2 patients in the splenectomy group. For patients in the splenectomy group, the average white blood cell nadir was 6.1 +/- 3.4 (range 0.3 to 14.7) on day

7.2. The average absolute neutrophil count was 5.2 +/- 3.6 (range 0.1 to 13.4), the average 5HT Receptor inhibitor Platelet nadir was 172.0 +/- 81.9 (range 3.0 to 381.0), and the average hemoglobin nadir was 7.5 +/- 1.0 (range 4.9 to 10.3). For patients in the non-splenectomy group, the average white blood cell nadir was 4.6 +/- 2.4 (range 0.5 to Inhibitors,research,lifescience,medical 13.2) on day 6.0. The average absolute neutrophil count was 3.9 +/- 2.7 (range 0.2 to 14.5), the average platelet nadir was 164.1 +/- 73.0 (range 6.0 to 426.0), and the average hemoglobin nadir was 8.2 +/- 1.8 (range 4.4 to 13.9). Hematologic toxicity grade by National Cancer Institute criteria is shown for white blood cell, platelets, and hemoglobin in Table 2. White blood cell toxicity was significantly lower in the splenectomy group compared to the non-splenectomy Inhibitors,research,lifescience,medical group (P=0.048). Platelet toxicity was not statistically significantly different between the two groups (P=0.24). Hemoglobin toxicity was significantly worse in the splenectomy group (P=0.003). There was no statistically significant difference in hematologic Inhibitors,research,lifescience,medical toxicity between those receiving mytomycin C and those receiving oxaliplatin (P=0.754). Table 2 Hematotoxicity

Thalidomide by splenectomy group Granulocyte colony stimulating factor was administered in 29% of splenectomy patients versus 43% of non-splenectomy patients (P=0.043). Granulocyte colony stimulating factor was administered for an average of 2.9 +/- 2.1 days (range 1.0 to 8.0) in the splenectomy group, versus an average of 3.3 +/- 3.3 days (range 1.0 to 18.0) in the non-splenectomy group. The difference in the average number of days treated with granulocyte colony stimulating factor was not statistically significant (P=0.61). During the post-operative period, there were significant differences in the number of red blood cell transfusions required for the splenectomy group compared to the non-splenectomy group (Table 3).

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>